Open AccessImplication of trans-11,trans-13 conjugated linoleic acid in the development of hepatic steatosis
Author(s) -
Barbara D. Pachikian,
Céline Druart,
Émilie Catry,
Laure B. Bindels,
Audrey M. Neyrinck,
Yvan Larondelle,
Patrice D. Cani
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0192447
Subject(s) - conjugated linoleic acid , lipogenesis , polyunsaturated fatty acid , linoleic acid , steatosis , biochemistry , lipid metabolism , triglyceride , metabolism , chemistry , fatty liver , sterol regulatory element binding protein , fatty acid , biology , sterol , medicine , cholesterol , endocrinology , disease
Scope Conjugated linoleic acids are linoleic acid isomers found in the diet that can also be produced through bacterial metabolism of polyunsaturated fatty acids. Our objective was to evaluate the contribution of fatty acid metabolites produced from polyunsaturated fatty acids by the gut microbiota in vivo to regulation of hepatic lipid metabolism and steatosis. Methods and results In mice with depleted n-3 polyunsaturated fatty acids, we observed an accumulation of trans -11, trans -13 CLA and cis -9, cis -11 conjugated linoleic acids in the liver tissue that were associated with an increased triglyceride content and expression of lipogenic genes. We used an in vitro model to evaluate the impact of these two conjugated linoleic acids on hepatic lipid metabolism. In HepG2 cells, we observed that only trans -11, trans -13 conjugated linoleic acids recapitulated triglyceride accumulation and increased lipogenic gene expression, which is a phenomenon that may implicate the nuclear factors sterol regulatory element binding protein 1c (SREBP-1c) and carbohydrate-responsive element-binding protein (ChREBP). Conclusion The trans -11, trans -13 conjugated linoleic acids can stimulate hepatic lipogenesis, which supports the conclusion that gut microbiota and related metabolites should be considered in the treatment of non-alcoholic liver disease.